4 oktober, 2018 Regulatoriskt AcuCort obtains regulatory approval to start bioequivalence study for the EU
7 september, 2018 Regulatoriskt AcuCort’s allergy medicine Dexa ODF has been manufactured and released according to Good Manufacturing Practice, GMP
21 juni, 2018 Regulatoriskt AcuCort signs agreement with the CRO Quinta-Analytica concerning the performance of bioequivalence studies
12 juni, 2018 Regulatoriskt AcuCort’s allergy treatment Dexa ODF is ready to be manufactured according to GMP (Good Manufacturing Practice) for clinical use
24 april, 2018 Regulatoriskt Correction and clarification concerning the expiry dates of AcuCort’s patents
16 april, 2018 Regulatoriskt AcuCort’s patent is granted with 1,349 days extended patent protection in the US